Insulet Corporation $PODD Shares Acquired by Hawk Ridge Capital Management LP

Key Points

• Hawk Ridge Capital Management LP increased its stake in Insulet Corporation by 64.8%, acquiring an additional 75,300 shares to bring its total holdings to 191,510 shares, which represents about 2.4% of its investment portfolio.
• Several large investors, including Zions Bancorporation and Larson Financial Group, also made significant adjustments to their positions in Insulet, indicating growing interest in the company during the first quarter.
• Insulet's recent quarterly earnings surpassed analyst expectations, with an EPS of $1.17 compared to the predicted $0.92, alongside a remarkable 32.9% year-over-year revenue growth.

Hawk Ridge Capital Management LP lifted its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 64.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 191,510 shares of the medical instruments supplier's stock after buying an additional 75,300 shares during the period. Insulet accounts for approximately 2.4% of Hawk Ridge Capital Management LP's holdings, making the stock its 21st biggest position. Hawk Ridge Capital Management LP owned 0.27% of Insulet worth $50,292,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC grew its position in shares of Insulet by 55.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock valued at $1,376,000 after buying an additional 1,867 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of Insulet by 85.1% during the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock valued at $236,000 after buying an additional 412 shares during the last quarter. QRG Capital Management Inc. grew its position in shares of Insulet by 75.6% during the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock valued at $533,000 after buying an additional 874 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in Insulet by 225.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock valued at $408,000 after purchasing an additional 1,075 shares during the period. Finally, State of Alaska Department of Revenue boosted its stake in Insulet by 2.6% during the 1st quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier's stock valued at $2,156,000 after purchasing an additional 210 shares during the period.

Analyst Ratings Changes

A number of research firms have issued reports on PODD. Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price for the company in a research note on Tuesday, May 13th. Truist Financial began coverage on shares of Insulet in a research note on Monday, June 16th. They set a "buy" rating and a $365.00 target price for the company. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Citigroup reissued a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $332.71.

Insulet Price Performance

Shares of NASDAQ:PODD traded up $1.96 during trading on Friday, reaching $348.43. The company had a trading volume of 498,473 shares, compared to its average volume of 584,368. The firm's fifty day moving average is $307.55 and its 200 day moving average is $289.86. The firm has a market capitalization of $24.53 billion, a PE ratio of 105.91, a price-to-earnings-growth ratio of 2.92 and a beta of 1.36. Insulet Corporation has a twelve month low of $211.27 and a twelve month high of $350.00. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business's revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.